Sakiris Spiro Kevin's Form 4/A amendment
AmendedIntelligent Bio Solutions Inc. (INBS) · filed Oct 10, 2023
- Accession no.
- 0001493152-23-036603
- Filed
- Oct 10, 2023
- Rule 10b5-1 plan
- Not checked
- Original filed
- Oct 6, 2023
This filing lists no transactions. It carries over 3 transactions from the original filing that it did not restate.
This amendment restates part of 0001493152-23-036581 (filed Oct 6, 2023). The transactions it did not restate still count and are listed below.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Sakiris Spiro KevinCIK 0001830957 | Officer (Chief Financial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
This filing has no transactions of this kind.
Carried over from the original filing
This amendment restates only part of the original filing. The original's other transactions still stand, and the trade tables on Livermore count them under this amendment.
From 0001493152-23-036581 (filed Oct 6, 2023).
Non-derivative securities (Table I)
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 4, 2023 | Common Stock | PPurchaseAcquired | +112,727 | –F1 | – | 117,427 | Indirect |
Derivative securities (Table II)
Footnotes on the original
The footnotes that the prices of these transactions refer to on the original filing.
- F1
The reported securities are included within 112,727 INBS Class A Units purchased by the reporting person for $0.55 per Unit. Each Unit consists of one share of the common stock, one warrant to purchase one share of Common Stock at an exercise price of $0.55 per share ("Series E Warrants"), and one warrant to purchase one share of Common Stock at an exercise price of $0.55 per share ("Series F Warrants"). The Warrants will be exercisable beginning on the effective date of such stockholder approvals as may be required by the applicable rules and regulations of the Nasdaq Capital Market (or any successor entity) to permit the exercise of the Warrants ("Warrant Stockholder Approval").
Referenced by the price of 1 transaction in Table I and 2 transactions in Table II.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
On October 6, 2023, the reporting person filed a Form 4 which inadvertently reported that, following his purchase of Class A Units, he indirectly owned 117,427 shares of the issuer's common stock. In fact, as reported in this amendment, the reporting person indirectly owned 117,472 shares of common stock.
- F2
These securities are held by Anest Holdings Pty Ltd, as trustee of ATF S&T Sakiris Superannuation Fund, of which Mr. Sakiris is a director.